Assessment of antibody responses to Anopheles SG6-P1 and Aedes N-term 34 kDa salivary peptides: a randomised human-challenge trial of controlled exposures to vector bites

V Chaumeau; EA Kearney; P Wasisakun; S Sawasdichai; AA Aung; PA Agius; TH Min; D da Silva Gonçalves; K O'Flaherty; A Rouers; S Aryalamloed; GN Htoo; MP Sue; NM Tha; N Chanida; G Gornsawun; S Chotirat; JA Simpson; L Rénia; F Nosten; FJI Fowkes

Journal article

Assessment of antibody responses to Anopheles SG6-P1 and Aedes N-term 34 kDa salivary peptides: a randomised human-challenge trial of controlled exposures to vector bites

V Chaumeau, EA Kearney, P Wasisakun, S Sawasdichai, AA Aung, PA Agius, TH Min, D da Silva Gonçalves, K O'Flaherty, A Rouers, S Aryalamloed, GN Htoo, MP Sue, NM Tha, N Chanida, G Gornsawun, S Chotirat, JA Simpson, L Rénia, F Nosten Show all

BMC Medicine | Published : 2026

DOI: 10.1186/s12916-026-04732-z

Abstract

BACKGROUND: Human antibodies against mosquito salivary proteins are proposed as proxy biomarkers of exposure to vector bites. This trial sought to characterise the boosting and decay dynamics of antibodies against Anopheles SG6-P1 and Aedes N-term 34kDa salivary peptides in a human challenge model of controlled exposure to the main Southeast Asian malaria and global dengue vectors. METHODS: In this single-centre, open-label, randomised, exploratory factorial trial, healthy volunteers aged 18-60 years with no history of recent travel to rural areas were recruited in Mae Sot, Thailand (ClincalTrials.gov: NCT04478370). Participants were randomly assigned to receive either 35 or 305 bites of mos..

View full abstract